Published in Br J Clin Pharmacol on August 01, 2002
Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol (2009) 1.57
Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials (2007) 1.28
Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol (2009) 1.25
Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP). Br J Clin Pharmacol (2012) 1.01
Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol. Br J Clin Pharmacol (2004) 0.95
Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci (2005) 0.93
Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports. Psychopharmacology (Berl) (2013) 0.90
The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol (2013) 0.87
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol (2012) 0.86
Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. Br J Clin Pharmacol (2005) 0.84
Stereoselective Inhibition of the hERG1 Potassium Channel. Front Pharmacol (2010) 0.83
Integrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitors. PLoS One (2013) 0.82
A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. Br J Clin Pharmacol (2011) 0.82
In silico assessment of drug safety in human heart applied to late sodium current blockers. Channels (Austin) (2014) 0.81
Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol (2011) 0.81
Modeling Rett Syndrome Using TALEN-Edited MECP2 Mutant Cynomolgus Monkeys. Cell (2017) 0.80
Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics. Can J Psychiatry (2015) 0.80
Psychotropic Drugs and Prolonged QTc Interval: Does it Really that Matter? Indian J Psychol Med (2016) 0.78
Serum magnesium concentrations in patients receiving sodium picosulfate and magnesium citrate bowel preparation: an assessment of renal function and electrocardiographic conduction. Clin Exp Gastroenterol (2015) 0.77
Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6-11 years-old than cumulative high doses of inhaled terbutaline. Br J Clin Pharmacol (2004) 0.75
Development of neuroleptic agents: pharmacogenetics and current safety issues of regulatory concern. Dialogues Clin Neurosci (2002) 0.75
Moxifloxacin-induced QTc interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study. Br J Clin Pharmacol (2015) 0.75
Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials. Invest New Drugs (2012) 0.75
Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. Trends Endocrinol Metab (2017) 0.75
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell (1995) 11.62
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell (1995) 10.18
Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med (1998) 8.49
[Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss (1966) 4.21
Torsades de pointes occurring in association with terfenadine use. JAMA (1990) 3.93
Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA (2000) 3.81
QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation (1978) 3.32
Mechanism of the cardiotoxic actions of terfenadine. JAMA (1993) 3.27
Low penetrance in the long-QT syndrome: clinical impact. Circulation (1999) 3.14
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA (1993) 3.01
Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA (1993) 2.78
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet (2000) 2.60
Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol (2001) 2.55
Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation (1998) 2.48
Use of terfenadine and contraindicated drugs. JAMA (1996) 2.23
A minK-HERG complex regulates the cardiac potassium current I(Kr). Nature (1997) 2.03
Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation (2000) 1.91
Drug-induced QT prolongation in women during the menstrual cycle. JAMA (2001) 1.87
Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther (1992) 1.68
Cardiotoxic effect with convulsions in terfenadine overdose. BMJ (1989) 1.65
Potassium channel down-regulation in heart failure. Cardiovasc Res (1998) 1.60
Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther (2000) 1.58
Torsade de pointes after astemizole overdose. Br Med J (Clin Res Ed) (1986) 1.58
Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med (1997) 1.50
Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians. Diabetologia (1998) 1.46
Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology (1998) 1.39
Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther (1996) 1.39
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol (2001) 1.37
Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus. Diabet Med (2001) 1.34
Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J (1996) 1.29
Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol (1991) 1.20
QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm Sci Technolo Today (1999) 1.16
Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys J (1995) 1.14
Sotalol, hypokalaemia, syncope, and torsade de pointes. Br Heart J (1984) 1.13
Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry (1989) 1.09
Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. Mol Pharmacol (1993) 1.09
Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol (1999) 1.09
Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother (1996) 1.08
Prolonged QT interval in hypertrophic and dilated cardiomyopathy in children. Am Heart J (1994) 1.05
Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther (2000) 1.00
Torsade de pointes due to quinidine: observations in 31 patients. Am Heart J (1984) 1.00
Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther (1991) 1.00
Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl) (1996) 0.96
Stereoselective effects of the enantiomers of bupivacaine on the electrophysiological properties of the guinea-pig papillary muscle. Br J Pharmacol (1991) 0.95
Pharmacogenetics of cardiac K(+) channels. Eur J Pharmacol (2000) 0.95
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) (1999) 0.95
Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: present and future implications. Biochem Pharmacol (1998) 0.92
Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther (1999) 0.92
QT interval prolongation and mortality in type 1 diabetic patients: a 5-year cohort prospective study. Neuropathy Study Group of the Italian Society of the Study of Diabetes, Piemonte Affiliate. Diabetes Care (2000) 0.91
Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol (2000) 0.91
Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. Cardiovasc Res (2001) 0.89
Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol (1996) 0.89
[Torsades de pointe. Apropos of 60 cases]. Ann Cardiol Angeiol (Paris) (1985) 0.89
Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective. J Clin Pharmacol (1999) 0.88
ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry (1987) 0.87
Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc (1997) 0.87
[Prolonged QTc intervals in Parkinson's disease--relation to sudden death and autonomic dysfunction]. No To Shinkei (1996) 0.86
Familial hypertrophic cardiomyopathy associated with prolongation of the QT interval. Z Kardiol (2000) 0.86
Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol (1998) 0.85
Molecular genetics of the long QT syndrome: two novel mutations of the KVLQT1 gene and phenotypic expression of the mutant gene in a large kindred. Hum Mutat (1998) 0.84
Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther (1996) 0.83
Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. Br J Clin Pharmacol (1996) 0.83
Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes: a meta-analysis. Diabetes Care (2000) 0.83
The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy (1999) 0.82
Abnormalities of the QT interval in primary disorders of autonomic failure. Am Heart J (1998) 0.82
Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Clin Pharmacol Ther (1997) 0.82
Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation. Br J Clin Pharmacol (2001) 0.82
Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval). Clin Ther (1999) 0.81
[Torsade de pointes. Apropos of 54 cases]. Ann Fr Anesth Reanim (1982) 0.81
Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol (1997) 0.79
The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development. J Pharmacol Toxicol Methods (2001) 0.79
Genotype and severity of long QT syndrome. Arch Pathol Lab Med (2001) 0.79
The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods. Hum Exp Toxicol (1998) 0.78
Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol (1993) 0.77
Basic mechanisms underlying prenylamine-induced 'torsade de pointes': differences between prenylamine and fendiline due to basic actions of the isomers. Curr Med Res Opin (1988) 0.77
The cardiac pharmacodynamics of therapeutic doses of sparfloxacin. Clin Ther (1999) 0.76
Prolonged QT and hypertrophic cardiomyopathy in two families with 10 sudden deaths. J Assoc Physicians India (1985) 0.76
The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. Eur J Clin Pharmacol (1987) 0.76
Severe cardiac arrythmia on cisapride. Prescrire Int (2000) 0.76